Tenax Therapeutics, Inc.
TENX· Nasdaq
TENXTenax Therapeutics, Inc.
Filed Aug 13, 2024 · 10-Q · 44 days after period end · 0001654954-24-010456
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$3.58M | -$1.11M | -$2.86M | -$1.72M |
| EPS Diluted | -$1.83 | — | — | -$0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end
